enGene Therapeutics
ENGN
34 hedge funds and large institutions have $275M invested in enGene Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
21% more capital invested
Capital invested by funds: $228M → $275M (+$47M)
13% more funds holding
Funds holding: 30 → 34 (+4)
3.47% more ownership
Funds ownership: 77.55% → 81.02% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$25.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$15.1M |
| 3 |
VA
VR Adviser
New York
|
+$11.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.3M |
| 5 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$7.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$6.63M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.21M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.28M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.28M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.48M |
ENGN Hedge Fund Activity: Q4 2024 in Review
34 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q4 2024, worth a combined $275M — up 21% from $228M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ENGN positions and 7 closed out — a net gain of 5 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Kynam Capital Management, adding an estimated $25.3M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $6.63M sold.
- 34 institutional investors held enGene Therapeutics (ENGN) as of Q4 2024, up from 30 in Q3 2024.
- Funds reported $275M of enGene Therapeutics stock for Q4 2024, up 21% quarter-over-quarter.
- 12 funds opened new enGene Therapeutics positions in Q4 2024 and 7 closed out, a net change of +5 holders.
- The largest enGene Therapeutics buyer in Q4 2024 was Kynam Capital Management, an estimated $25.3M added.
- The largest enGene Therapeutics seller in Q4 2024 was Janus Henderson Group, an estimated $6.63M sold.
Based on aggregated 13F filings for Q4 2024.